GLPwatch
Papers (12034)
Page 138 of 201, ranked by citation count.
- Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.
- Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons.
- Impact of the injectable weight-loss medications, glucagon-like peptide-1 receptor agonists, on reproductive health in non-polycystic ovary syndrome state.
- New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.
- Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.
- Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
- The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism.
- Liraglutide for Adolescents with Obesity. Reply.
- [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].
- [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
- Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.
- Pharmaceutical approval update.
- Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.
- An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.
- Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.
- Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
- Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.
- Modeling the impact of preplanned dose titration on delayed response.
- Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
- Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes.
- Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial.
- Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
- Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress.
- Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.
- Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.
- Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.
- Reducing CV risk in diabetes: An ADA update.
- Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
- Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
- Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway.
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.
- [Effect of exendin-4 on lipid deposition in skeletal muscle of diet-induced obese mice and its underlying mechanism].
- Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.
- Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes.
- Dose-dependent erythema nodosum after initiation of semaglutide.
- Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.
- Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform.
- Liraglutide in Children and Teens with Type 2 Diabetes. Reply.
- [Results of the LEADER study: current evidence and perspectives in research].
- Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.
- Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.
- Future Medications for Obesity and Clinical Implications.
- The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.
- Efficacy of Semaglutide in Reactive Hypoglycemia Related to Dumping Syndrome after Bariatric Surgery.
- Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy.
- GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm.
- New Drug: Tirzepatide (Mounjaro<sup>™</sup>).
- Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.
- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.
- Liraglutide promotes diabetic corneal epithelial and nerve regeneration by suppressing oxidative stress via the PI3K/AKT signalling pathway.
- GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.
- Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
- Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.
- Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.
- In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
- Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis.
- Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats.
- Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.